Ισραήλ - Εβραϊκά - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

Ισραήλ - Εβραϊκά - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - norepinephrine bitartrate as monohydrate - תמיסה להזרקה - norepinephrine bitartrate as monohydrate 2.0 mg / 1 ml - norepinephrine - norepinephrine - blood pressure control in certain acute hypotensive stages (e.g. pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infraction, septicemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest and profound hypotension.

Ισραήλ - Εβραϊκά - Ministry of Health

genmedix - norepinephrine as bitartrate 1 mg/ml - solution for injection - norepinephrine - blood pressure control in certain acute hypotensive stages (e.g. pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infraction, septicemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest and profound hypotension.

Ισραήλ - Εβραϊκά - Ministry of Health

taro pharmaceutical industries ltd - glyceryl trinitrate 1 mg/ml - solution for infusion - glyceryl trinitrate - nitroglycerin is indicated for: 1. control of hypertension during cardiac surgery. 2. unresponsive congestive heart failure associated with acute myocardial infarction. 3. treatment of anginal pectoris in hospitalised patients who have not responded to organic nitrates and/or beta blockers. 4. maintenance of controlles hypotension during surgical procedurs.

Ισραήλ - Εβραϊκά - Ministry of Health

taro pharmaceutical industries ltd - glyceryl trinitrate 1 mg/ml - solution for infusion - glyceryl trinitrate - control of hypertension during cardiac surgery. unresponsive congestive heart failure associated with acute myocardial infarction. treatment of angina pectoris in hospitalised patients who have not responded to organic nitrates and/or beta blockers. maintenance of controlled hypotension during surgical procedures.

Ισραήλ - Εβραϊκά - Ministry of Health

ami technologies ltd., israel - peflurten - תרחיף להזרקה - peflurten 1.1 mg/ml - other cardiovascular system diagnostic radiopharmaceuticals - echocardiography: definity (perflutren injectable suspension) is indicated for contrast-enhanced ultrasound imaging of cardiac structures (ventricular chambers and endocardial borders) and function (regional wall motion) in adult patients with suboptimal echocardiograms. abdominal ultrasound : definity is also indicated for contrast-enhanced ultrasound imaging of the liver and kidneys in adult patients to improve the evaluation of pathology.

Ισραήλ - Εβραϊκά - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 20 mg/ml - ibuprofen

Ισραήλ - Εβραϊκά - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Ισραήλ - Εβραϊκά - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

Ισραήλ - Εβραϊκά - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or